Aloe Therapeutics is developing a first-in-class platform immunotherapy for solid tumors, called Allo-Immunotherapy (AIM-001). AIM-001 is a localized, nontraditional cell-based immunotherapy implanted at the tumor site during biopsy or tumor removal surgery. AIM-001 acts as “bait” for the immune system by triggering the powerful transplant rejection immune response to trigger an influx of activated immune cells at the tumor site. An activated immune system and “hot” tumor, full of activated immune cells, increases effectiveness of common cancer therapies, like checkpoint immunotherapy. Turn cold tumors hot and hot tumors hotter for patients with difficult-to-treat solid tumors and limited therapeutic options
Company Details
- Address
- Germantown, Md, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://aloetherapeutics.com
- HQ
- Germantown, MD
Aloe Therapeutics Questions
Aloe Therapeutics's website is http://aloetherapeutics.com
Aloe Therapeutics's LinkedIn profile is https://www.linkedin.com/company/aloe-therapeutics
Aloe Therapeutics's industry is
Biotechnology Research
Aloe Therapeutics's top competitors are
Odin Materials,
Rt Microdx,
Discova,
Zebratox,
Kipostech,
The Pennycress Company,
Rubywell,
Coffee Elf Inc.,
Manglovo Health,
Vita Therapeutics.
Aloe Therapeutics's categories are Biotechnology Research
